Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Prometheus Biosciences (Nasdaq: RXDX) announced that CEO Mark McKenna will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 3:40 PM ET. The event will be accessible via a live and archived webcast on the company's investor relations page. Prometheus is focused on precision medicine for immune-mediated diseases, with its lead candidate, PRA023, currently in Phase 2 trials for Ulcerative Colitis and Crohn's disease, and plans to initiate a trial for systemic sclerosis-associated interstitial lung disease.

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO, will conduct a virtual fireside chat at the 11^th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 3:40 PM ET.

A live and archived webcast of the virtual fireside chat will be available via the Events & Webcasts page on the Investor section of the Prometheus Biosciences website.

About Prometheus Biosciences

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The Company’s precision medicine platform, Prometheus360^TM, combines proprietary machine learning-based analytical approaches with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.

The Company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody (mAb) for the treatment of immune-mediated diseases including Ulcerative colitis (UC), Crohn’s disease (CD), and the newly identified systemic sclerosis-associated interstitial lung disease (SSc-ILD). The Company is currently conducting a Phase 2 trial in UC patients and a Phase 2a trial in CD patients, each utilizing a proprietary genetic-based companion diagnostic designed to identify patients who are predisposed to increased expression of TL1A and therefore potentially more likely to respond to PRA023. The company also plans to initiate a Phase 2 clinical trial for PRA023 in SSc-ILD in the first quarter of 2022.

Prometheus Biosciences Contact:
Noel Kurdi
VP Investor Relations and Communications
(646) 241-4400
nkurdi@prometheusbiosciences.com

Media contact:
Juniper Point
Amy Conrad
(858) 914-1962
media@prometheusbiosciences.com

FAQ

What is Prometheus Biosciences' ticker symbol?

The ticker symbol for Prometheus Biosciences is RXDX.

When will Mark McKenna conduct the fireside chat?

Mark McKenna will conduct the fireside chat on February 16, 2022, at 3:40 PM ET.

How can I watch the fireside chat by Prometheus Biosciences?

The fireside chat can be watched via a live and archived webcast on the Investor section of the Prometheus Biosciences website.

What is the lead candidate of Prometheus Biosciences?

Prometheus Biosciences' lead candidate is PRA023, an IgG1 humanized monoclonal antibody for immune-mediated diseases.

What diseases does PRA023 target?

PRA023 targets Ulcerative Colitis, Crohn's disease, and systemic sclerosis-associated interstitial lung disease.

What clinical trials is Prometheus Biosciences currently conducting?

Prometheus Biosciences is conducting Phase 2 trials for PRA023 in patients with Ulcerative Colitis and Crohn's disease.

What is the purpose of the Prometheus360 platform?

The Prometheus360 platform aims to identify novel therapeutic targets and develop candidates for immune-mediated diseases.